Skip to main content

CMPS

Stock
Health Care
Medical Care Facilities

Performance overview

CMPS Price
Price Chart

Forward-looking statistics

Beta
1.02
Risk
74.18%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

compass pathways is a life sciences company dedicated to accelerating patient access to evidence-based innovation in mental health. our first major initiative is developing psilocybin therapy through late-stage clinical trials in the eu and us for patients with treatment-resistant depression. we are developing psychoactive care pathways based on advances in neuroscience, psychotherapy, psychopharmacology and digital platforms.

Company info

SectorHealth Care
IndustryMedical Care Facilities
Employees186
Market cap$474.6M

Fundamentals

Enterprise value$33.9M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity16.39

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.99
Dividend per share
Revenue per share
Avg trading volume (30 day)$13M
Avg trading volume (10 day)$28M
Put-call ratio

Macro factor sensitivity

Growth+6.7
Credit+3.9
Liquidity-3.4
Inflation+0.9
Commodities+2.3
Interest Rates-3.4

Valuation

Dividend yield0.00%
PEG Ratio-1.58
Price to sales
P/E Ratio-1.58
Enterprise Value to Revenue
Price to book1.55

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day
Ex. dividend day

News

COMPASS Pathways (CMPS) Upgraded to Buy: Here's Why

COMPASS Pathways (CMPS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research (July 8, 2025)
Vizsla Silver, COMPASS Pathways And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were mixed this morning, with the Nasdaq futures gaining around 0.1% on Monday.

Benzinga (June 23, 2025)
Peter Thiel-backed psychedelic start-up increases stake in Compass Pathways

Atai Life Sciences, the Peter Thiel-backed psychedelic start-up, has increased its stake in Compass Pathways.

CNBC (November 29, 2021)
Compass Pathways CEO on mushroom-based therapy for depression: 'The data was breathtaking'

George Goldsmith, Compass Pathways co-founder and CEO, joins 'Closing Bell' to discuss why its shares are down more than 20 percent despite positive data on its therapeutic treatment for depression.

CNBC Television (November 9, 2021)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free